Methods
Inclusion criteria required patients to be 3-65 years of age with a peanut-specific IgE 6 7 kU/l and/or a positive peanut skin prick test and a history of an allergic reaction to peanut ( table 1 ) . Many of the subjects had had positive oral food challenges to peanut before entering the study. Patients underwent a modified rush day identical to a previously published protocol [4] where increasing amounts of peanut protein were ingested until the maximum dose (cumulative 12 mg peanut protein) was reached or a reaction occurred. The following day, they were brought back to repeat the highest tolerated dose. If there was no reaction within 1 h, they were sent home with daily doses. Patients were instructed to keep a daily diary of doses and any potential reactions with severity determined by subjective assessment (mild, moderate or severe). Patients returned to the Clinical Translational Research Unit (CTRU) every 2 weeks where daily dosing diaries were reviewed and dose escalations occurred to a maximum maintenance dosage of 4,000 mg of peanut protein. Any reactions in the CTRU were graded based on Bock's criteria [7] . Research staff kept in close contact with patients and families to investigate any significant adverse events, and subjects had 24-hour contact information for all study personnel in case of a significant reaction or dosing question.
Results
Twenty-four subjects received 6,662 doses. Twentytwo of these reported symptoms during either home doses or doses in the CTRU. Overall, there were 1,023 symptoms recorded, 84% of which were mild and either self-resolved or resolved with antihistamines, 13% were moderate and 3% were severe. Of the severe reactions, three, in separate patients, were treated with epinephrine. One was given in the CTRU following a dose escalation due to severe abdominal pain not responsive to multiple doses of antihistamines. Two were given at home following previously tolerated doses, one with severe abdominal pain following an episode of diarrhea and the second following multiple episodes of emesis with moderate throat pain unresponsive to antihistamines. For all 3 subjects, a single injection of epinephrine improved the clinical symptoms within a few minutes. None of these reactions resulted in discontinuation of therapy. All home reactions requiring epinephrine were associated with either exercise or bathing following the dose of peanut. Any patients who experienced a moderate to severe reaction had their next dose decreased to a dose that was previously tolerated without any adverse symptoms. These patients were also asked to premedicate with H 1 +/-H 2 antihistamines. These two strategies worked well to prevent and attenuate adverse reactions. However, 1 patient (subject F) while on 12 mg of peanut protein had persistent abdominal pain and cough. The parents were not interested in premedicating or treating with antihistamines and the patient dropped out of the study. Of all the symptoms in all subjects, abdominal pain was the most common (34%), followed by oropharyngeal pruritus (25%) and lip pruritus (9%) ( fig. 1 ). Eleven percent of total symptoms occurred in the CTRU at Stanford and 89% occurred at home. On average 13.6% of home doses per patient (range 0-74%) resulted in allergic reactions.
Although not statistically significant due to a small sample size, there seemed to be an increased percentage of dose administrations resulting in reactions around the 25-to 50-mg dose levels ( fig. 2 ). These reactions were generally mild, resolving spontaneously or with antihistamines, although some delayed dose advancement at the next clinic visit. There were no differences in reaction severity or frequency between the adult (n = 2) and pediatric (n = 22) patients, although again this was not statistically significant because of the small sample size. 
Discussion
The safety of OIT for peanut allergic patients has long been a concern in the design and implementation of trial protocols [8] [9] [10] [11] [12] . Since OIT necessitates ingesting the offending food, and ingestion of peanut allergen is responsible for more anaphylactic deaths than any other food allergen, it is easy to understand the trepidation of doctors and patients. However, peanut allergy is also a disease without an available modifying treatment and we live in a society where accidental exposures are almost unavoidable.
Several well-conducted pilot studies have indicated that although respiratory reactions to carefully administered peanut OIT occur, they may not be frequent [4] [5] [6] 13] and our data supports the hypothesis that peanut OIT can be done safely. These data must be viewed with scrutiny, however, given the small sample sizes. Key components of safely administering an OIT regimen include experienced study personnel, extensive patient education, adherent patients and families, and ready access to lifesaving therapies at the study site and at home.
As has recently been published, OIT is not yet ready to be considered the standard of care, and should only be conducted within the rigors of an IRB-approved and monitored research study [8, 12] . Several aspects of OIT need to be understood prior to routine implementation. More research is needed to further delineate how to individualize treatment, determine which patients must be treated with the most caution, which can move through the dosing ladder with greater speed and how to best prevent reactions. Certain dosing levels may be more likely to cause reactions or may function as 'threshold' doses, a dose level at which an individual subject has more reactions. Escalations may need to be slowed around these dose levels and may be able to be advanced more quickly once higher levels are reached. The optimal goal dose for OIT should be investigated. Furthermore, more biochemical data is needed to help practitioners understand which patients will only become desensitized, thereby necessitating ongoing daily dosing, and which will become tolerant to peanuts, and how to know when an individual has crossed from the former into the latter category.
There are several ongoing studies looking at the safety and efficacy of peanut OIT in mostly pediatric populations. Our study is ongoing in both adults and children, and further phase 2 and 3 studies are needed to obtain optimal methods for best clinical practices and doses for peanut OIT.
